ContraFect (NASDAQ:CFRX) Receives New Coverage from Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of ContraFect (NASDAQ:CFRX – Free Report) in a research report released on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

ContraFect Trading Down 28.0 %

Shares of NASDAQ CFRX opened at $0.05 on Wednesday. ContraFect has a 12 month low of $0.04 and a 12 month high of $13.02. The firm has a market capitalization of $535,000.00, a price-to-earnings ratio of 0.00 and a beta of 0.29. The business has a 50-day moving average of $0.24 and a 200-day moving average of $0.83.

ContraFect (NASDAQ:CFRX – Get Free Report) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.16. On average, analysts predict that ContraFect will post -3.44 earnings per share for the current year.

Institutional Trading of ContraFect

Several hedge funds and other institutional investors have recently bought and sold shares of CFRX. Envestnet Asset Management Inc. purchased a new stake in ContraFect in the first quarter worth approximately $41,000. Dimensional Fund Advisors LP boosted its stake in ContraFect by 62.9% in the first quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock worth $412,000 after buying an additional 43,564 shares in the last quarter. Vanguard Group Inc. boosted its stake in ContraFect by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,551,898 shares of the biotechnology company’s stock worth $5,664,000 after buying an additional 11,064 shares in the last quarter. State Street Corp boosted its stake in ContraFect by 33.5% in the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock worth $474,000 after buying an additional 32,563 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in ContraFect by 1.2% in the first quarter. Goldman Sachs Group Inc. now owns 407,031 shares of the biotechnology company’s stock valued at $1,486,000 after purchasing an additional 4,948 shares during the last quarter. Hedge funds and other institutional investors own 7.85% of the company’s stock.

About ContraFect

(Get Free Report)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus.

See Also